Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel Marine Compounds: Anticancer or Genotoxic?

Jamal M. Arif, Amal A. Al-Hazzani, Muhammed Kunhi

    Journal of Biomedicine & Biotechnology
    |July 9, 2004
    PubMed
    Summary

    Marine compounds show promise for cancer drug development, but preclinical testing in early carcinogenesis models is crucial for clinical trial success. This review highlights the importance of appropriate screening and biomarkers.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Protein arginine methyltransferase 6 mediates cardiac hypertrophy by differential regulation of histone H3 arginine methylation.

    Heliyon·2020
    Same author

    Synthesis, characterization and cytotoxicity evaluation of some new platinum(II) complexes of tetrazolo[1,5-a]quinolines.

    European journal of medicinal chemistry·2004
    Same author

    Multiplicity of strand incision at G:T base mismatches in DNA by human cell extracts.

    Biochemistry·2004
    Same author

    Substrate specificity and sequence preference of G:T mismatch repair: incision at G:T, O6-methylguanine:T, and G:U mispairs in DNA by human cell extracts.

    Biochemistry·2002

    Area of Science:

    • Marine natural products
    • Drug discovery and development
    • Preclinical cancer research

    Background:

    • Marine organisms yield diverse bioactive compounds with anticancer potential.
    • Few marine-derived anticancer drugs are approved; many face clinical trial attrition.
    • Current preclinical testing often relies on tumor xenografts, potentially missing efficacy in early cancer stages.

    Purpose of the Study:

    • To critically review the importance of preclinical evaluation for marine anticancer compounds.
    • To discuss reasons for clinical trial failures of potential anticancer agents.
    • To examine screening tests and biomarker selection in marine anticancer drug development.

    Main Methods:

    • Literature review and critical analysis of preclinical and clinical data.
    • Discussion of established and emerging animal carcinogenesis models.
    • Evaluation of screening assays and biomarker utility.

    Main Results:

    • Preclinical models that mimic early carcinogenesis stages are vital for identifying effective marine anticancer agents.
    • Inadequate preclinical data from relevant models contributes to clinical trial failures.
    • Appropriate biomarker selection enhances the predictive value of preclinical studies.

    Conclusions:

    • Enhanced preclinical evaluation, including models of carcinogenesis initiation, is essential for advancing marine anticancer compounds.
    • Strategic use of screening tests and biomarkers can improve the success rate of marine-derived anticancer drugs in clinical trials.
    • Further research integrating diverse preclinical models and robust biomarkers is needed to fully realize the therapeutic potential of marine natural products.

    Related Experiment Videos